ARIAD has an exclusive license to pioneering technology and patents related to methods of treating human disease through modulation of the cell-signaling of a protein called NF-κB, and the discovery and development of drugs to regulate NF-κB cell-signaling activity. NF-κB can be generally thought of as a "biological switch" that can be turned off using these treatment methods to treat disorders such as inflammation, cancer, sepsis and osteoporosis.
We permit broad use of our NF-κB intellectual property at no cost by investigators at academic and not-for-profit institutions to conduct non-commercial research. Our goal is to license our NF-κB technology to pharmaceutical and biotechnology companies conducting research on the discovery of drugs that modulate NF-κB cell signaling and/or marketing such drugs.
One of our NF-κB patents is the subject of two outstanding lawsuits and a proceeding before the Unites States Patent and Trademark Office. For updated information about these proceedings, see our most recent filings with the Securities and Exchange Commission (including reports on Forms 8-K, 10-K, and 10-Q).
For more information about partnering and licensing opportunities with ARIAD, please contact: Richard W. Pascoe at rich.pascoe@ariad.com or (617) 494-0400.
